铜绿假单胞菌下呼吸道感染诊治专家共识

标题: 铜绿假单胞菌下呼吸道感染诊治专家共识
title: Expert consensus on the management of Pseudomonas aeruginosa lower respiratory tract infections
版本: 更新版
version: Updated
分类: 专家共识
classification: Experts consensus
领域: 综合
field: Comprehensive guideline
国家和地区: 中国
Country and region: China
指南使用者: 医生、护士、感染控制人员、临床微生物检测技术员、医院管理者
Guide users: Physicians, nurses, infection control personnel, clinical microbiology lab technicians, hospital administrators
证据分级方法:
Evidence grading method: GRADE
制定单位: 中华医学会呼吸病学分会感染学组
Formulating unit: Chinese Thoracic Society Pulmonary Infection assembly
注册时间: 2021-02-01
Registration time:
注册编号: IPGRP-2021CN028
Registration number:
指南制订的目的: 铜绿假单胞菌(Pseudomonas aeruginosa, PA)是一种革兰阴性杆菌,也是临床最常见的非发酵菌,在自然界广泛分布,可作为正常菌群在人体皮肤生长,还可污染医疗器械甚至消毒液。PA是医院内感染重要的条件致病菌,具有易定植、易变异和多耐药的特点。下呼吸道是医院内感染最常见的发生部位, ,如由多重耐药PA ( multidrug resistant P aeruginosa, MDR-PA )所致则病死率高,治疗困难,因此规范PA下呼吸道感染的诊断和治疗具有特别重要的意义。近年来,在PA下呼吸道感染的耐药情况、检测技术、治疗手段和预防等方面取得了一些进展,因此,中华医学会呼吸病学分会感染学组发起并组织专家更新2014年制定的《铜绿假单胞菌下呼吸道感染诊治专家共识》。
Purpose of the guideline: Pseudomonas aeruginosa (PA) is one of the most common non-fermentative bacterium in the clinical setting, which is widely distributed in nature and can grow as a normal flora in human skin and contaminated medical devices and even disinfectant solutions.PA is an important conditional pathogen of hospital-acquired infections and the multi-drug resistance (MDR) rate is high. The lower respiratory tract is the most common site of hospital-acquired infections, and if it is caused by MDR-PA, the morbidity and mortality rate is high and the treatment is difficult, so it is particularly important to standardize the diagnosis and treatment of PA lower respiratory tract infections. In recent years, progress has been made in the drug resistance epidemiology, detection technology, treatment options and prevention of PA lower respiratory tract infections, therefore, the Chinese Thoracic Society Pulmonary Infection assembly initiated and organized experts to update the Expert consensus on the management of Pseudomonas aeruginosa lower respiratory tract infections developed in 2014.